BMS, Avidity add another link to cardiovascular partnership with $100M expansion

Bristol Myers Squibb seems to have found a friend in Avidity Biosciences, as the two add a second link to a heart-focused research partnership for $100 million upfront.

The two companies tied the first deal in 2021, when Avidity announced a research collaboration with BMS-owned MyoKardia. The pact focused on discovering if Avidity’s antibody oligonucleotide conjugates (AOCs), a type of RNA therapeutic, could be used for cardiac tissues.